Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The FDA aims to make a decision by April 8, 2026
Here's a development that aims to keep your blood pressure in check. Literally!
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
For patients with resectable early-stage gastric and gastroesophageal junction cancers
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
Subscribe To Our Newsletter & Stay Updated
